Screening for nasopharyngeal carcinoma using Epstein-Barr virus tests
Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
Sun Yat-sen University · NCT05447169
This study is testing whether certain blood tests for the Epstein-Barr virus can help find nasopharyngeal cancer earlier in family members of patients who have it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 11625 (estimated) |
| Ages | 30 Years to 62 Years |
| Sex | Male |
| Sponsor | Sun Yat-sen University (other) |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05447169 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of Epstein-Barr virus (EBV) antibody and DNA screening methods in first-degree relatives of patients with nasopharyngeal carcinoma. The investigators will conduct tests on various EBV antibodies and DNA using techniques such as ELISA and quantitative polymerase chain reaction. The goal is to identify the most effective screening method for detecting nasopharyngeal carcinoma in a high-risk population. Participants will be residents of Southern China who meet specific age and health criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are males aged 30-62 who are first-degree relatives of nasopharyngeal carcinoma patients and have no prior history of the disease.
Not a fit: Patients with a history of nasopharyngeal carcinoma or significant cardiovascular, liver, or kidney diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection methods for nasopharyngeal carcinoma, potentially increasing survival rates.
How similar studies have performed: Other studies have explored EBV as a biomarker for nasopharyngeal carcinoma, suggesting potential success in similar approaches.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * residents in Southern China * 30-62 years old * male * a first-degree relative of at least one nasopharyngeal carcinoma patient * no medical record of nasopharyngeal carcinoma * Eastern Cooperative Oncology Group score of 0-2 * be able to comprehend, sign, and date the written informed consent document to participate in the study Exclusion Criteria: * history of nasopharyngeal carcinoma * heavy cardiovascular, liver or kidney disease * on systemic steroid or immunosuppressant treatment or active autoimmune disease
Where this trial is running
Guangzhou, Guangdong
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Study coordinator: Ming-Yuan Chen, MD, PhD
- Email: chmingy@mail.sysu.edu.cn
- Phone: 86-20-8734-3361
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Carcinoma Screen, EBV DNA, EBV antibody